Immortalized cell lines are tumorous cells that do not stop replicating or cells which have been artificially operated to proliferate forever and can, thus, be grown over the several generations. These cell lines are anticipated to grow due to rise in innovative technologies and vaccine production.
Besides, ability of cell line culture to offer more physiologically pertinent information and more precise data in-vitro examinations has led the these cell line culture systems to become the acceptable in contrast to media culture.
The growing application in pharmaceutical and biotech companies and hospitals, growing number of patients in the need of organ transplantation, and rise in patient population affected by the cancer are major drivers driving market growth. However, high cost of the equipment and developing stable strain of the cell line and preventing and maintaining it from the contamination may hinder growth of the market.Segment Overview
The growing demand for the organ donation due to shortage in availability of organs is driving need for artificially produced biological cells. According to the U.S. Department of the Health and Human Services Organ Procurement and the Transplantation Network (OPTN), as of Nov 2016, almost 121,678 patients were waiting for life-saving organ transplant.
This growing demand for organ transplant is predictable to drive growth of the market during forecast period. Moreover, increasing application in the biotech and pharmaceutical companies and the hospitals and increase in patient population affected by the cancer are expected to support the market growth. On other hand, high cost of equipment and the developing stable strain of cell line coupled with the maintaining and preventing it from the contamination is expected to hamper market growth.Regional Overview
The North America is projected to dominate global immortalized cell line market over the forecast period. This is accredited to increase in occurrence of cancer, presence of well-established biotechnology and pharmaceutical industry, growing awareness of the immortalized cell lines, and the strong research funding.
The European market for the immortalized cell line is predictable to be second-largest during forecast period. Growing government support, rising cases of the cancer and well-developed technology are anticipated to boost growth of market in this region.
Asia-Pacific is projected to be fastest-growing market owing to the growing expenditure on the healthcare by government and the private sector companies. Furthermore, the rising awareness about healthcare and the large untapped patient population have also led to increased focus of the key players on the expansion in the region. Competitor overview
In April 2018, Company Lonza Group, AG declared the opening of worlds largest devoted cell-and-gene-therapy plant facility in the Pearland, Greater Houston, (U.S.). The site was built in expectation of rising demand from the developers of cell and the gene therapies.
In August 2017, company named, Thermo Fisher Scientific acquired the Patheon for USD 7.2 million. Patheon’s CDMO amenities are likely to accompany Thermo Fisher Scientific’s technologies designed to upkeep with the clinical trials, research, and production.Key Players
- Thermo Fisher Scientific
- ATCC (American Type Culture Collection Inc.)
- Sartorius AG
- Lonza Group, AG
- Merck KGaA
- Selexis SA
- WuXi App Tec
- European Collection of Authenticated Cell Cultures (ECACC)
- Corning Incorporated
- Virus Induction
- Inactivation of Tumor Suppression Genes
- HTERT Expression
- Drug Discovery
- Tissue Engineering & Regenerative Medicine
- Vaccine Production
- North America
- Rest of Europe
- South Korea
- Rest of Asia-Pacific
- Saudi Arabia
- Rest of LAMEA